A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma

@inproceedings{Chandramohan2013ANR,
  title={A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma},
  author={Vidyalakshmi Chandramohan and Darell D Bigner},
  booktitle={Oncoimmunology},
  year={2013}
}
Both the amplification of the gene coding for wild-type (wt) epidermal growth factor receptor (EGFR) and the overexpression of the EGFR deletion mutant, commonly known as EGFRvIII, are hallmarks of glioblastoma. We have recently reported a novel, recombinant immunotoxin, D2C7-(scdsFv)-PE38KDEL, that targets both wt EGFR and EGFRvIII, exhibiting potent antineoplastic effects against established murine gliomas. 

1 Figure or Table

Connections & Topics

Mentioned Connections BETA
We have recently reported a novel , recombinant immunotoxin , D2C7-(scdsFv)-PE38KDEL , that targets both wt EGFR and EGFRvIII , exhibiting potent antineoplastic effects against established murine gliomas .
All Topics